Health claims for food products in Europe are permitted if the nutrient has been shown to have a beneficial nutritional or physiological effect. This paper defines health claims related to bone health and provides guidelines for the design and the methodology of clinical studies to support claims

Avouac, B.

Bruyère, O.

Chevalier, T.

Coxam, V.

Fabien-Soulé, V.

Kanis, J. A.

Kaufman, J.-M.

Reginster, J.-Y.

Rizzoli, R.

Tsouderos, Y.

English

PubMed

Health claims for food products in Europe are permitted if the nutrient has been shown to have a beneficial nutritional or physiological effect. This paper defines health claims related to bone health and provides guidelines for the design and the methodology of clinical studies to support claims. Introduction Regulation (EC) no. 1924/2006 on nutrition and health claims targeting food products was introduced in Europe stating that health claims shall only be permitted if the substance in respect of which the claim is made has been shown to have a beneficial nutritional or physiological effect. The objective of this paper is to define health claims related to bone health and to provide guidelines for the design and the methodology of clinical studies which need to be adopted to assert such health claims. Methods Literature review followed by a consensus discussion during two 1-day meetings organized by the Group for the Respect of Ethics and Excellence in Science (GREES). Results The GREES identified six acceptable health claims related to bone health based on the potential of food products to show an effect on either the bioavailability of calcium or osteoclast regulatory proteins or bone turnover markers or bone mineral density or bone structure or fracture incidence. The GREES considers that well-designed human randomized controlled trial on a relevant outcome is the best design to assess health claims. The substantiation of health claim could also be supported by animal studies showing either an improvement in bone strength with the food product or showing the relationship between changes induced by the food product on a surrogate marker and changes in bone strength. Conclusion The consensus reached is that the level of health claim may differ according to the surrogate endpoint used and on additional animal studies provided to support the claim

Bruyere, Olivier, O.

Rizzoli, René, R.

Coxam, Véronique

Avouac, Bernard, B.

Chevalier, Thierry, T.

Fabien-Soule, Véronique, V.

Kanis, John A., J. A.

Kaufman, Jean-Marc, J.-M.

Tsouderos, Yannis, Y.

Reginster, Jean-Yves, J.-Y.

HAL Clermont Université

Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)

Hal-Diderot

O. Bruyère

R. Rizzoli

V. Coxam

B. Avouac

T. Chevalier

V. Fabien-Soulé

J. A. Kanis

J.-M. Kaufman

Y. Tsouderos

J.-Y. Reginster

Crossref

Osteoporosis International

Springer - Publisher Connector

Health claims for food products in Europe are permitted if the nutrient has been shown to have a beneficial nutritional or physiological effect. This paper defines health claims related to bone health and provides guidelines for the design and the methodology of clinical studies to support claims. 
Introduction : Regulation (EC) no. 1924/2006 on nutrition and health claims targeting food products was introduced in Europe stating that health claims shall only be permitted if the substance in respect of which the claim is made has been shown to have a beneficial nutritional or physiological effect. The objective of this paper is to define health claims related to bone health and to provide guidelines for the design and the methodology of clinical studies which need to be adopted to assert such health claims. 
Methods : Literature review followed by a consensus discussion during two 1-day meetings organized by the Group for the Respect of Ethics and Excellence in Science (GREES). 
Results : The GREES identified six acceptable health claims related to bone health based on the potential of food products to show an effect on either the bioavailability of calcium or osteoclast regulatory proteins or bone turnover markers or bone mineral density or bone structure or fracture incidence. The GREES considers that well-designed human randomized controlled trial on a relevant outcome is the best design to assess health claims. The substantiation of health claim could also be supported by animal studies showing either an improvement in bone strength with the food product or showing the relationship between changes induced by the food product on a surrogate marker and changes in bone strength. 
Conclusion : The consensus reached is that the level of health claim may differ according to the surrogate endpoint used and on additional animal studies provided to support the claim

Bruyère, O

Rizzoli, R

Coxam, V

Avouac, B

Chevalier, T

Fabien-Soulé, V

Kanis, JA

Kaufman, Jean

Tsouderos, Y

Reginster, J-Y

Ghent University Academic Bibliography

HAL Descartes

Summary: Health claims for food products in Europe are permitted if the nutrient has been shown to have a beneficial nutritional or physiological effect. This paper defines health claims related to bone health and provides guidelines for the design and the methodology of clinical studies to support claims. Introduction: Regulation ( EC ) no. 1924/2006 on nutrition and health claims targeting food products was introduced in Europe stating that health claims shall only be permitted if the substance in respect of which the claim is made has been shown to have a beneficial nutritional or physiological effect. The objective of this paper is to define health claims related to bone health and to provide guidelines for the design and the methodology of clinical studies which need to be adopted to assert such health claims. Methods: Literature review followed by a consensus discussion during two 1-day meetings organized by the Group for the Respect of Ethics and Excellence in Science ( GREES ). Results: The GREES identified six acceptable health claims related to bone health based on the potential of food products to show an effect on either the bioavailability of calcium or osteoclast regulatory proteins or bone turnover markers or bone mineral density or bone structure or fracture incidence. The GREES considers that well-designed human randomized controlled trial on a relevant outcome is the best design to assess health claims. The substantiation of health claim could also be supported by animal studies showing either an improvement in bone strength with the food product or showing the relationship between changes induced by the food product on a surrogate marker and changes in bone strength. Conclusion: The consensus reached is that the level of health claim may differ according to the surrogate endpoint used and on additional animal studies provided to support the claim

Kanis, John A.

Reginster, Jean-Yves

ACU Research Bank

Assessment of health claims in the field of bone: A view of the Group for the Respect of Ethics and Excellence in Science (GREES)

Rizzoli, René

Archive ouverte UNIGE

An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice.

Bone strength and ultrastructure.

Bone turnover markers in the management of postmenopausal osteoporosis.

Bone turnover markers: understanding their value in clinical trials and clinical practice.

Calcium bioavailability in relation to bone health.

Calcium intake, calcium bioavailability and bone health.

Codex recommendations on the scientific basis of health claims.

Diagnosis, prophylaxis, and treatment of osteoporosis.

Evidence for health claims on foods: how much is enough? Introduction and general remarks.

Health claims in Europe: new legislation and PASSCLAIM for substantiation.

Imaging techniques for evaluating bone microarchitecture.

Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines. Osteoporos Int 9:379–393

Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 41:308–317 Osteoporos Int

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly.

Microarchitecture, the key to bone quality. Rheumatol Oxf 48(Suppl 4):iv3–iv8

Nutrition: its role in bone health.

PASSCLAIM— bone health and osteoporosis.

Pointillart A

Recommendations for measurement of bone mineral density and identifying persons to be treated for osteoporosis. Rheum Dis Clin North Am 32:681–689

The design and use of animal models for translational research in bone tissue engineering and regenerative medicine.

Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 45:221–258 198 Osteoporos Int

https://hal.archives-ouvertes.fr/hal-00939644

Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)

Abstract

Similar works

Full text

Available Versions